Selected article for: "antibody response and neutralize antibody response"
Author: Liu, Yuan; Dai, Lianpan; Feng, Xiaoli; Gao, Ran; Zhang, Nan; Wang, Bin; Han, Jianbao; Zou, Qingcui; Guo, Xiling; Zhu, Hua; Liu, Jiangning; Qin, Chuan; Zhang, Yi; Bao, Linlin; Li, Minghua
Title: Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA
  • Cord-id: ablzy52i
  • Document date: 2021_9_27
    • ID: ablzy52i
    Snippet: In the face of the emerging variants of SARS-CoV-2, there is an urgent need to develop a vaccine that can induce fast, effective, long-lasting and broad protective immunity against SARS-CoV-2. Here, we developed a trimeric SARS-CoV-2 S protein vaccine candidate adjuvanted by PIKA, which can induce robust cellular and humoral immune responses. The results showed a high level of neutralizing antibodies induced by the vaccine was maintained for at least 400 days. In the study of non-human primates,
    Document: In the face of the emerging variants of SARS-CoV-2, there is an urgent need to develop a vaccine that can induce fast, effective, long-lasting and broad protective immunity against SARS-CoV-2. Here, we developed a trimeric SARS-CoV-2 S protein vaccine candidate adjuvanted by PIKA, which can induce robust cellular and humoral immune responses. The results showed a high level of neutralizing antibodies induced by the vaccine was maintained for at least 400 days. In the study of non-human primates, PIKA adjuvanted S-trimer induced high SARS-CoV-2 neutralization titers and protected from virus replication in the lung following SARS-CoV-2 challenge. In addition, the long-term neutralizing antibody response induced by S-trimer vaccine adjuvanted by PIKA could neutralize multiple SARS-CoV-2 variants and there is no obvious different among the SARS- CoV-2 variants of interest or concern, including B.1.351, B.1.1.7, P.1, B.1.617.1 and B.1.617.2 variants. These data support the utility of S-trimer protein adjuvanted by PIKA as a potential vaccine candidate against SARS-CoV-2 infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s43556-021-00054-z.

    Search related documents:
    Co phrase search for related documents
    • ab response and acute respiratory syndrome coronavirus: 1, 2, 3, 4
    • acid inducible and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acid inducible and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acid inducible and adjuvant activity: 1
    • acid inducible gene and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acid inducible gene and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acid inducible gene and adjuvant activity: 1
    • activation maturation and acute respiratory syndrome: 1, 2, 3, 4
    • activation maturation and acute respiratory syndrome coronavirus: 1, 2, 3
    • activation stimulatory and acute respiratory syndrome: 1
    • acute respiratory syndrome and additional file: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adjuvant activity: 1, 2
    • acute respiratory syndrome and adjuvant pika: 1
    • acute respiratory syndrome and adjuvant time: 1
    • acute respiratory syndrome and adjuvant twice: 1, 2
    • acute respiratory syndrome coronavirus and additional file: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome coronavirus and adjuvant activity: 1, 2
    • acute respiratory syndrome coronavirus and adjuvant pika: 1
    • acute respiratory syndrome coronavirus and adjuvant time: 1